NYMX Insider Trading
Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 54.00%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00
Nymox Pharmaceutical Insider Trading History Chart
This chart shows the insider buying and selling history at Nymox Pharmaceutical by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Nymox Pharmaceutical Share Price & Price History
Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 07/6/2023 05:00 PM ET
Nymox Pharmaceutical Insider Trading History
Nymox Pharmaceutical Institutional Trading History
Data available starting January 2016
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.
Read More on Nymox Pharmaceutical
Today's Range
Now: N/A
52 Week Range
Now: N/A
Volume
932,700 shs
Average Volume
94,622 shs
Market Capitalization
$18.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.64